# Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study

> **NCT02531295** · PHASE1 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 5 (actual)

## Conditions studied

- HIV
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Euphorbia kansui extract powder prepared as tea

## Key facts

- **NCT ID:** NCT02531295
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-15
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Pause on clinical trial enrollment due to grant funding cuts after COVID-19
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531295, "Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02531295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*